The treatment with CD274-blocking antibodies was reported to efficiently reduce the tumor burden and restore cytotoxicity activities of CD8+ T cells in a murine chronic lymphoblastic leukemia model [30]. The gene discussed is CD8A; the disease is neoplasm.